TNDM
Tandem Diabetes Care, Inc.
TNDM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
TNDM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TNDM's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
TNDM PE Valuation
TNDM has no meaningful PE right now: it lost money over the past year.
TNDM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TNDM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TNDM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.72 | +$2.33 |
| Q2 2026 | -$0.93 | +$2.16 |
| Q1 2026 | -$1.40 | +$1.38 |
| Q4 2025 | -$3.07 | -$1.61 |
| Q3 2025 | -$3.05 | -$1.12 |
| Q2 2025 | -$3.09 | -$1.00 |
| Q1 2025 | -$2.78 | -$0.61 |
| Q4 2024 | -$1.46 | +$1.98 |
TNDM is still losing money, but far less than before: $0.72 per share over the past year, against $3.48 at its worst in mid-2023.
TNDM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $283.7M | +14% |
| Q2 2026 | $254.6M | +5.8% |
| Q1 2026 | $247.2M | +5.5% |
| Q4 2025 | $290.4M | +2.7% |
| Q3 2025 | $249.3M | +2.2% |
| Q2 2025 | $240.7M | +8.5% |
| Q1 2025 | $234.4M | +22% |
| Q4 2024 | $282.6M | +44% |
TNDM's revenue has grown year over year for 11 quarters in a row: $284M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +8.3 points |
| Q2 2026 | -5.4% | +16 points |
| Q1 2026 | -7% | +45 points |
| Q4 2025 | 2.9% | +3.1 points |
| Q3 2025 | -9.2% | +1.5 points |
| Q2 2025 | -22% | -7.7 points |
| Q1 2025 | -52% | -30 points |
| Q4 2024 | -0.2% | +18 points |
TNDM's operating margin was −0.8% last quarter, up 8.3 points from the same quarter a year ago.
TNDM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | -232% |
| Q2 2026 | -$38.7M | -$23M |
| Q1 2026 | $4.8M | +$26M |
| Q4 2025 | $3.1M | -59% |
| Q3 2025 | $4.2M | -81% |
| Q2 2025 | -$15.7M | -$4M |
| Q1 2025 | -$21.2M | -$8.8M |
| Q4 2024 | $7.6M | +$20.1M |
TNDM's free cash flow was −$36M over the past year, against −$25M the year before.
TNDM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -16.5x | Net Cash |
| Q1 2022 | -3.8x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
| Q3 2021 | -2.7x | Net Cash |
| Q2 2021 | -3.0x | Net Cash |
| Q1 2021 | -8.3x | Net Cash |
| Q4 2020 | -37.9x | Net Cash |
TNDM has more cash than debt.
TNDM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 30.2 | Neutral |
TNDM's weekly RSI is 48 (neutral) and its Stochastic is 30 (neutral).
TNDM PE vs Healthcare Sector
| Metric | TNDM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TNDM has no meaningful PE right now: it lost money over the past year.
TNDM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.9 | 3.4% above |
| 20 week MA | $18.1 | 3.4% below |
| 50 week MA | $19.1 | 8.4% below |
| 100 week MA | $19.9 | 12% below |
| 200 week MA | $26.5 | 34% below |
TNDM has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
TNDM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $93.9 | +56% |
| 2021 | $93.9 | $151.8 | +62% |
| 2022 | $151.8 | $42.0 | -72% |
| 2023 | $42.0 | $29.6 | -30% |
| 2024 | $29.6 | $36.9 | +25% |
| 2025 | $36.9 | $22.4 | -39% |
| 2026 YTD | $22.4 | $17.5 | -22% |
TNDM has finished lower in three of the last six years. It's down 22% so far in 2026.